Search research articles
Contact Us
Filters
Showing results (451-460 of 578) with videos related to
Page
of 58
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
March 12, 2024
Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer
Romain Boidot, Michael G B Blum, Marie-Pierre Wissler, et al.
The Lancet. Oncology
|
April 12, 2021
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
Robert L Coleman, Domenica Lorusso, Christine Gennigens, et al.
Oncogene
|
November 9, 2023
Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial
Celine Callens, Manuel Rodrigues, Adrien Briaux, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 25, 2020
Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy
Angelina Tjokrowidjaja, Chee K Lee, Michael Friedlander, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2016
Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer
James M Flanagan, Angela Wilson, Chail Koo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 13, 2015
European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners--First Update 2015
Andreas du Bois, Alexander Reuss, Eric Pujade-Lauraine, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 4, 2016
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer
Christian Marth, Ignace Vergote, Giovanni Scambia, et al.
Breast Cancer Research and Treatment
|
February 12, 2008
Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive
Ben Van Calster, Isabelle Vanden Bempt, Maria Drijkoningen, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 22, 2022
Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group
Ignace Vergote, Els Van Nieuwenhuysen, Stefanie De Waele, et al.
Cellular Oncology (Dordrecht, Netherlands)
|
May 15, 2012
Genomic aberrations relate early and advanced stage ovarian cancer
Afra Zaal, Wouter J Peyrot, P M J J Berns, et al.
Page
of 58
Search research articles
Search
Showing results (451-460 of 578) with videos related to
Sort By:
Page
of 58
European Journal of Cancer (Oxford, England : 1990)
|
March 12, 2024
Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer
Romain Boidot, Michael G B Blum, Marie-Pierre Wissler, et al.
The Lancet. Oncology
|
April 12, 2021
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
Robert L Coleman, Domenica Lorusso, Christine Gennigens, et al.
Oncogene
|
November 9, 2023
Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial
Celine Callens, Manuel Rodrigues, Adrien Briaux, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 25, 2020
Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy
Angelina Tjokrowidjaja, Chee K Lee, Michael Friedlander, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2016
Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer
James M Flanagan, Angela Wilson, Chail Koo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 13, 2015
European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners--First Update 2015
Andreas du Bois, Alexander Reuss, Eric Pujade-Lauraine, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 4, 2016
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer
Christian Marth, Ignace Vergote, Giovanni Scambia, et al.
Breast Cancer Research and Treatment
|
February 12, 2008
Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive
Ben Van Calster, Isabelle Vanden Bempt, Maria Drijkoningen, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 22, 2022
Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group
Ignace Vergote, Els Van Nieuwenhuysen, Stefanie De Waele, et al.
Cellular Oncology (Dordrecht, Netherlands)
|
May 15, 2012
Genomic aberrations relate early and advanced stage ovarian cancer
Afra Zaal, Wouter J Peyrot, P M J J Berns, et al.
Page
of 58